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Abstract Despite an impressive increase in survival rate over the last decades, there is still a 
need to improve the survival of specific subgroups of Wilms tumor (anaplastic, metastatic, 
bilateral) and to decrease the late effects of treatment in term of renal function and heart toxicity. 
We aim to explore new areas of improvement, from diagnosis to treatment: in the field of 
radiology the increased use of MRI and exploration of its diffusion weighted imaging 
capabilities to predict WT histology at diagnosis and for preoperative assessment; in biology the 
emergence of new biomarkers that could be integrated into the decision-making process; and 
surgical techniques with more accurate indication of nephron sparing surgery that is no longer 
reserved for bilateral WT and the minimally invasive approach. The long-term outcome of 
patients with WT should thus be a strong indicator of the improvement in adapting and 
personalizing the treatment to each individual.  
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Introduction on general considerations in Wilms Tumor  
Impressive progress has been made for children with Wilms Tumor (WT) with long-term cure 
rates greater than 85% collectively. A significant amount of this success is due to two 
multidisciplinary cooperative groups, Société Internationale d’Oncologie Pédiatrique (SIOP) and 
Children’s Oncology Group (COG-formerly the National Wilms Tumor Study Group 
[NWTSG]).1 Although there are some philosophical differences in approach, these groups have 
conducted a series of well-designed clinical and biological studies that have provided a large 
body of evidence-based knowledge to help establish the optimal treatments for children WT.2-5 
Recent investigations have looked at the impact of centralized surgical, radiological and 
pathological review; in vivo histological response through MRI research, response-based 
outcomes, new biomarkers (somatic and genetic predisposition) and impact of nephron sparing 
surgery (NSS) in selected cases. The goal is to develop a more individual risk-adapted approach 
that optimizes event free survival (EFS) and minimizes late effects. Despite these advances, 
challenges remain: a significant number of children with WT (e.g. anaplastic histology or stage 
IV disease) have unacceptable EFS and/or late effects. The purpose of this state-of-the-art review 
is to present the current and future status of the biological understanding, diagnosis and treatment 
of a child with WT. 
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Presentation Diagnosis and tumor staging: comparative and innovative aspects of diagnosis 
Most children with WT present with an asymptomatic palpable mass found by a parent or 
physician. Up to 20% of children present with hematuria, hypertension, fever and/or flank pain.6 
Rarely a child can present with an acute abdomen secondary to tumor rupture and uncontrolled 
bleeding. Health systems and access to health are important aspects of how a disease is 
diagnosed. An interesting study by Pritchard-Jones et al compared the health system of Germany 
and the United Kingdom (UK) with respect to the diagnosis of renal tumors in children.7 In the 
UK primary care givers are generalists (“family doctors) whereas in Germany children have 
direct access to pediatricians. Pritchard-Jones et al demonstrated that in the UK, children present 
with a larger size tumor and later stage than those in Germany. There was a 3% difference in 
EFS/ overall survival (OS). The small sample size and generally effective treatment regimens for 
children with WT likely played a role but the results are though provoking nevertheless. In 
Germany, a greater proportion of WT are detected incidentally whereas in the UK, the majority 
presented with tumour-related symptoms, suggesting that the primary care system for children in 
the UK may not be ideal for early detection of renal tumors. 
Ultrasound (US) with doppler and CT scan or MRI are used to define the origin, extent and 
metastatic sites for renal masses. For many years chest X-Ray was the imaging study to assess 
pulmonary metastasis, however this has largely been replaced by CT scan. When CT was first 
used, it resulted in smaller lung nodules being detected, creating both diagnostic and therapeutic 
challenges.8-11 Alternatively it led to realization that not all patients with pulmonary disease 
required pulmonary radiation. Over the last several years, MRI imaging of the abdomen has 
increased over CT scan, however CT scan of the chest is still preferred to assess metastatic lung 
disease. 
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SIOP protocols and COG protocols differ in the initial treatment approach to the tumors. SIOP 
protocols prefer initial chemotherapy (with or without a biopsy to determine pathology) followed 
by surgery and adjuvant therapy with chemotherapy and/or radiation. Staging, risk assessment in 
most cases is done after the initial surgery. COG protocols prefer an initial nephrectomy 
followed by adjuvant chemotherapy and/or radiation if required. Final abdominal and disease 
staging is done after surgery but the factors used for staging classification are different (Table 1). 
Risk stratification for both protocols also includes different factors and use of biological markers 
and response. Furthermore although many of the chemotherapy drugs are similar, the timing and 
dosing of the chemotherapy are different in each protocol and in COG protocols surgery alone 
can be the only therapy. As expected over the years, these differences in approaches have often 
resulted in debates about “which is better”, however in reality both philosophical approaches 
have excellent EFS and OS for the standard risk tumors and more challenges in treating higher 
risk patients. What is more useful  in the authors opinion is to examine how each approach has 
improved understanding of tumor biology and treatment as well as stimulating research. For 
example one area of controversy has been the impact of a diagnostic biopsy on the risk of local 
recurrence and tumor staging. Patients treated on a COG protocol who underwent an open or 
imaged based renal biopsy because the treating team felt the tumor was unresectable have always 
been treated as stage III diseases. In addition those patients with a large intra-operative tumor 
spill were also treated as stage III disease. Alternatively if a patient underwent an intraoperative 
biopsy and at the same time had a nephrectomy, or during surgery had a small rupture these 
patients were treated as stage II on COG protocols. A paper by Shamberger et al examined 
surgical factors that predicted local recurrence from the NWTS-4 study.12 In a nested case 
control study, it showed local tumor recurrence was significantly increased if there was a tumor 
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spill regardless of small or large and if there was an intraoperative biopsy followed by a 
nephrectomy. Based on these results, the most recent COG studies made all spills (small or 
large) and any intraoperative biopsy a stage III criterion. This resulted in 11 patients (of 
approximately 400) being upstaged from II to III.13   
SIOP studies have also examined the impact of biopsy on local recurrence.  SIOP currently does 
not make all patients stage III when they biopsy their patients. Interestingly, UK patients are all 
biopsied at diagnosis by percutaneous cutting needle biopsy, preferably with a co-axial technique 
to obtain multiple cores. In the UKW3 trial running from 1991 to 2001, the two approaches were 
compared, the SIOP approach being associated with a biopsy at diagnosis (in contrast to the 
usual practice in Europe). This study showed an association between biopsy and any local 
relapse following univariate analysis but this lost formal statistical significance once anaplastic 
histology and increasing tumor size were taken into account. For distant relapse, biopsy was less 
clearly associated in univariate analysis. Indeed, older age and anaplastic histology were the 
overriding factors associated with metastatic relapse .14 As the small number of events limited 
the multivariate analysis, the study was extended to the whole SIOP 2001 trial and suggested that 
in SIOP protocols an upfront biopsy does not increase the risk of local relapse .15 How these 
results will affect future staging decision in COG studies within the groups’ treatment and risk 
stratification is unclear.  
Risk based therapy for renal tumors requires appropriate staging and risk stratification. WT also 
need both an abdominal stage and a disease stage. This can sometime be challenging for an 
institution which may only treat one or two cases each year. To help address this issue the COG 
study ARENO3B2 study (biology and risk classification) provided real time (within 7 days) 
central review of pathology, radiology and surgery followed by a risk classification for a 
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therapeutic study.16 This process showed that up to 20% of patients may have a change in 
interpretation based on central review as compared to institutional review. To date this has been 
done with over 6000 patients. SIOP has used central review to improve the quality of staging and 
histological risk classification by centralized national and international pathology panel review.17 
National review of imaging at diagnosis has been performed in Germany, and more recently in 
the UK, and is planned as part of the forthcoming SIOP-RTSG “UMBRELLA” study. 
The spread of MRI as the best imaging for diagnosis and follow-up has pushed its use as a very 
useful research tool in accurately predicting WT histology with the development of diffusion-
weighted images (DWI). DWI is a MR technique that provides information on the biophysical 
properties of tissues such as cell density, microstructure and microcirculation .18  By tracking the 
microscopic rate of water diffusion within tissues, it defines an apparent diffusion coefficient 
(ADC) that showed inverse correlation with tumor cellularity.19 Very recently, it has been shown 
that high-risk blastemal-type WT had a lower ADC value compared with intermediate-risk 
stromal, regressive and mixed-type WT and that no significant difference in ADC exists between 
blastemal-type and intermediate-risk epithelial-type WT .20 The predominant viable tissue 
subpopulation in every stromal-type WT underwent a positive shift in the mean ADC value after 
chemotherapy [Hales 2015].20 Such evaluation in the pre-operative chemotherapy phase may be 
of value in planning the timing of nephron-sparing surgery, especially in bilateral tumours. 
 
Approaches to surgical treatment in unilateral Wilms tumor, including metastatic disease 
What are the goals of the surgery and how it impacts further therapy? 
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The goals of surgery are to perform a safe operation, remove the kidney without intraoperative 
spill, sample lymph nodes, and document all findings, such as preoperative or intraoperative 
tumor rupture, extension into other structures and the presence of peritoneal metastasis. Failure 
to sample lymph nodes is the most common mistake made by surgeons and without it, the child 
cannot be properly staged. Some children have very favorable tumors and may not need 
chemotherapy or radiation therapy to achieve a cure, BUT the lymph node status must be known. 
Preoperative rupture and peritoneal metastasis mandate whole abdomen radiation and increased 
chemotherapy. Intraoperative spill from the tumor, ureter or vascular system mandates flank 
radiation and increased chemotherapy. Failure to give radiation/chemotherapy in these situations 
increases the risk of relapse. Obtaining central venous access where appropriate with a tunnel 
catheter or port should also be done at the same time if possible. A discussion with your 
anesthesia team about post-operative pain management should also occur prior to surgery.  
 
Standard technique 
Surgery is usually performed through a transperitoneal transverse approach, allowing a complete 
exposure of the abdomen. The essential difference between COG and SIOP approach is the time 
for surgery, upfront for COG and after first line chemotherapy for SIOP. The standard procedure 
is a total nephro-ureterectomy with lymph nodes (LN) sampling. Although it has been proven 
that the absence of LN sampling is a risk factor for recurrence 12, there are no formal 
recommendations for the number to sample. In a recent retrospective study from COG, a 
minimum of seven LN sampled increased the chances of detecting a metastasis but after 
controlling for tumor histology and stage, the number of LNs sampled did not predict EFS 
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variations .21 In SIOP 93-01 study, change in tumor volume under preoperative chemotherapy 
was not a predictor for LN status at surgery, although larger initial volume was associated with a 
higher risk of LN invasion .22 
The major risk of surgery is the rupture of the tumor with intraoperative spill into the abdomen. 
This risk has been assessed at 9.7% for 1131 patients enrolled in AREN03B2 whereas in SIOP 
studies, it has been estimated between 2.8 and 6% .23,24 The difference is likely explained by 
tumor shrinkage and less vascularity following chemotherapy that renders the tumor firmer to 
handle. Not all SIOP tumors are biopsied prior to initiating chemotherapy. Misdiagnosis rates as 
high as 8% and use of inappropriate treatment in 5.2% have been reported although this has 
dropped to below 1% recently 17,25,26]  
 
Vascular extension 
WT extension may occur through the renal vein into the inferior vena cava and up to the atrium. 
In large published series, caval extension was reported between 2% and 5% and atrial extension 
in 0.2% to 1.2% .27,28 Intraoperative management of a tumor thrombus requires proximal and 
distal vascular control. In case of renal vein thrombus, the thrombus should be gently milked out 
although extensive thrombus may be best managed with a venotomy to facilitate thrombus 
mobilization .29 Sometimes, the thrombus adheres to the intimal layer of the vein, leading to a 
piecemeal removal that will be responsible for upstaging the tumor and increasing the burden of 
treatment with possible risks on long-term morbidity . The most important is to manage these 
patients with a multidisciplinary team, including particularly cardiac surgeons to perform 
cardiopulmonary bypass if the thrombus is up to the atrium .30  
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Metastatic extension 
Metastatic extension is most often to the lungs or the liver and complete metastatic remission 
may be achieved with chemotherapy alone. These patients have the better outcome. There are 
few data on the role of complete surgical excision of persistent but responding metastases, 
though this is usual practice in some centers. There are more convincing data on the benefit of 
radiotherapy in slowly responding lung metastases. The major challenge is defining clinically 
significant lung metastases at initial presentation owing to the increased quality of CT scan that 
finds pulmonary nodules never seen before on X-ray. The impact of these ”CT-only” nodules is 
still to be determined although a recent COG analysis found that patients with CT-only lung 
lesions may have improved EFS but not OS from the addition of doxorubicin but do not appear 
to benefit from pulmonary radiation .31 In SIOP 2001 study, EFS and OS were inferior for 
patients with “CT-only” nodules compared to those without any doubtful nodules at diagnosis 
but the outcome was not significantly better in those treated with 3-drug chemotherapy .10 
However, both EFS/OS of the “CT-only” group were intermediate between those with localized 
disease and normal chest CT scan and those with metastatic disease visible on CXR. In the 
recent COG trial (ARENO533) one aim was to withhold pulmonary radiation for those patients 
who had complete resolution of pulmonary disease after 6 weeks of DD4A. 119/302 patients 
(39%) responded. Twenty four patients recurred within 2 years with 22 in the lung, one just in 
the abdomen and one had a second malignancy.  Thus 95/119 avoided pulmonary radiation. 
There were also some patients who had stable disease or had only 1 or 2 remaining lesions. It is 
possible that some of these patients had benign lesions, necrotic WT, or well-differentiated WT 
that may not require radiotherapy and could be cleared by thoracoscopy with small lesions 
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sometimes requiring image-guided localization. Future research is needed to investigate this 
possibility.  
 
Nephron sparing surgery in unilateral WT 
Partial nephrectomy is well established for bilateral WT but an area of controversy for unilateral 
WT. The goal of preserving renal function is laudable but has to be balanced with the 
exceedingly low rate of long-term renal dysfunction after total nephrectomy32-34  and the 
equivocal high-rate of stage III patients due to positive margins .35,36 Another consideration is 
that the main causes of renal failure in children with WT are disease progression and exposure to 
abdominal radiation. Only 3 to 9 % of non-syndromic patients treated according to SIOP and 
COG seem to fulfill NSS criteria .36,37 New guidelines from the next SIOP protocol have defined 
strict indications of NSS for unilateral WT: unifocal tumor restricted to one pole of the kidney 
with an estimated volume of less than 300 ml at diagnosis, no preoperative rupture, no venous or 
local extension and enough remnant healthy kidney tissue to avoid hyper filtration .38 
 
Place of laparoscopy 
The decision to use minimally invasive surgery (MIS) for WT should be made after weighing 
risks and benefits. From an early experience of 24 WT resected by transperitoneal laparoscopy 
within SIOP 2001, the authors concluded at the feasibility of the procedure, though challenging 
and requiring huge expertise by operating surgeons .39 Recognized indications for MIS in WT 
were small tumors not crossing the midline, i.e. the lateral edge of the vertebra at the time of 
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surgery being a certain limit, that have no venous extension, no adhesions to adjacent organs or 
preoperative rupture or spillage. MIS was not performed for tumors diameter bigger than 8 cm 
but size in itself was not considered as an absolute contra indication .40 These criteria are similar 
to those for NSS but NSS overcomes MIS and should be performed each time it is feasible. As 
for open approach, lymph nodes should be taken away safely and properly   
 
Horseshoe kidney 
The incidence of horseshoe kidney in WT patients approximates 0.5% [Neville 2002]. The main 
problem is the recognition at diagnosis of the presence of horseshoe kidney on imaging to fully 
assess the precise anatomy of both tumor and kidney for the most accurate surgical planning. 
Horseshoe kidney is not a contra indication to upfront surgery but may exhibit higher surgical 
complications rate with injuries to the collecting system .41 
 
Surgical Complications   
Intestinal obstruction is the most frequent complication (5.1%), followed by extensive 
hemorrhage (1.9%), wound infection (1.9%), and vascular injury (1.5%).  Factors associated 
with an increased risk of complications include intravascular tumor extension nephrectomy 
performed through a flank or paramedian incision tumor diameter of 15 cm or larger. 
Surgery only for patients with WT 
A review of NWTS1-4 found that the use of adjuvant therapy did not enhance the already 
excellent outcomes of children age 2 or younger with stage 1 favorable histology WT with 
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tumors less than 550 grams.42 For NWTS-5, if a child met these criteria, a surgery only arm was 
offered.43  The 8-year EFS for surgery-only was 84%; for the patients receiving EE-4A 
chemotherapy, it was 97% (P=0.002).  One death was observed in each group. The estimated 5-
year OS was 98% and 99% respectively (P = 0.70). Thus, 85% of the infants avoided any 
chemotherapy, while those who did receive it for relapse, were treated with three agents, 
vincristine, actinomycin D and doxorubicin (DD-4A), resulting in an OS equivalent to the group 
who received chemotherapy. The most recent COG study ARENO532 confirmed this 
observation with 116 patients treated without chemotherapy, with a 4-year EFS and OS of 89.7% 
(84-95%) and 100% respectively.44  
 
Risk stratification and overall oncological therapy – who gets what chemotherapy and the 
indications for radiotherapy (545 words) 
Risk stratification is a key factor to determine the most appropriate treatment for patients with 
WT for both COG and SIOP. The difference lies in that COG protocols include age at diagnosis, 
tumor weight and loss of heterozygosity (LOH) of 1p and 16q in favorable histology (FH) 
patients in their decision-making process at diagnosis. The most recent series of unilateral WT 
studies have just been completed and the 4 year  EFS and OS outcomes are shown in Table 2 
.SIOP protocol uses stage and histological risk group assigned by assessment of the tumour’s 
response to neoadjuvant chemotherapy to stratify patients but the recent emergence of 1q gain as 
a new biomarker of recurrence risk is likely to change the future consideration of biomarkers in 
the determination of subsequent therapeutic regimens .45,46 Before considering 1q gain for 
clinical use, the heterogeneity of its expression within the tumor needs to be fully assessed and 
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its prognostic significance needs to be validated in an independent sample set.47 Recently, 
several new Wilms tumour genes have been discovered . This has opened up the possibility of 
further biomarkers for risk stratification with implications for genetic predisposition to WT and 
consequences for long term renal function. 48 
Despite these findings, challenges to better treat WT with non-FH, stage IV and V WT and 
relieve the burden of chemotherapy and radiotherapy in more favorable groups remain. The 
results of the international, multicenter, open-label, non-inferiority, phase 3, randomized SIOP 
WT 2001 trial, comparing children with stage II-III intermediate-risk WT assessed after delayed 
nephrectomy showed that doxorubicin does not need to be included in treatment of stage II-III 
intermediate risk WT when the histological response to preoperative chemotherapy is 
incorporated into the risk stratification, thus limiting late cardio toxicity.49 
However, the combination of unique biological identifiers that would explain the relapse of stage 
II patients who do not have known elevated risk of recurrence at diagnosis is pending. The 
current COG trial AREN0532 protocol is examining the impact of intensifying therapy and 
adding doxorubicin for stage II FH WT with combined LOH 1p and 16q alone.  
Diffuse anaplasia has been the first identified risk factor for recurrence and several National WT 
Studies (NWTS) have proved the efficacy of cyclophosphamide and etoposide in addition to a 3-
drug regimen associated vincristine, dactinomycin and doxorubicin. In NWTS-5, 4-year relapse-
free survival for patients with stages II-IV diffuse anaplastic WT (DAWT) treated with 
vincristine, doxorubicin, cyclophosphamide, and etoposide, plus radiotherapy (Regimen I) was 
55%. AREN0321 showed that Regimen UH-1, a more intensive regimen containing carboplatin 
in addition to agents used in Regimen I, and Regimen UH-2 (UH-1 plus Vincristine, Irinotecan) 
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for patients with stage II-IV DAWT improved EFS (69%, 95%CI 56-80%) albeit with 
considerable increased cardiac, lung and hepatic toxicity.50 This high toxicity leads to look for 
novel therapeutic approaches, with a more favorable therapeutic benefit ratio, such as integration 
of biologic therapies, rather than via chemotherapeutic intensification, particularly for patients 
with advanced-stage disease and perhaps with biologically defined subsets, potentially those with 
p53 mutation or loss .51,52 
Stage IV WT means spread of the disease beyond the kidney, most often to the lungs. Treatment 
goals are to control the local/regional extension of the disease and the management of metastases 
with both chemotherapy and radiotherapy. Concerns about the treatment toxicity and findings of 
SIOP suggest that radiotherapy omission in rapid early responders might be feasible. The current 
COG study for stage IV WT (AREN0533) tested dose intensification for patients with slow 
incomplete response when CT lung metastases were assessed at week 6 and subsequently treated 
with regimen M (vincristine, dactinomycin, doxorubicin and cyclophosphamide/etoposide) and 
showed an estimated 3-year EFS and OS of 88% (95%CI: 81-93%) and 92% (95%CI: 86-96%) 
respectively, that favorably compared with historical controls .53 
 
Surgery for Bilateral Wilms Tumor and Unilateral High Risk Patients  
Children with BWT or a predisposition to bilateral tumors are a group with poor EFS (<70%) 
and a higher rate of renal failure (14% compared to <1% for unilateral patients). Although 
clinical trials have been performed in children with unilateral WT, it was not until 2009 that the 
first formal BWT study was started. The Children’s Oncology Group Study AREN0534 is the 
first multicenter, prospective, protocol-driven study of children with BWT, recommending 
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immediate use of 3 drug (VA + doxorubicin) to test if this would maximize the likelihood for 
NSS.  The SIOP 2001 trial also included a recommended treatment protocol for bilateral WT 
with 2 drug preoperative chemotherapy. Neither study has yet reported. Both groups recommend 
an attempt at NSS after 2-4 cycles. More than 4 cycles is not associated with an improved 
outcome and may increase the risk of anaplasia. Biopsy is not necessary in most cases before 
initiation of chemotherapy, but is strongly recommended in cases where there are unusual 
features (e.g. over the age of 8 years, atypical intra-abdominal findings on imaging). In 20 % of 
BWT cases, the pathology is not the same bilaterally; therefore it is important to sample both 
kidneys. After two cycles of chemotherapy the tumors should be re imaged to assess response if 
there is poor (<50%) response, bilateral biopsies should be performed to determine whether there 
is anaplastic or rhabdomyomatous changes, though it should be noted that needle biopsy often 
fails to detect diffuse anaplasia in unilateral cases. 54  
MRI and 3D imaging is very important in assessing response to chemotherapy and resectability. 
It is important to note that the tumor compresses normal renal parenchyma and that radiographic 
tumor characteristics may underestimate the proportion of BWT that are amenable to NSS.55  
MRI has become more widely used in cases of BWT especially in those with predisposition 
syndromes such as WAGR/BWS. The children with inherently abnormal kidney architecture are 
predisposed to nephrogenic rests and thus WT.  Due to the sensitivity of MRI the abnormal 
kidney architecture can appear as “lesions” which can be confusing. These lesions are usually 
less than a cm and will not change on repeat MRI. These lesions are particularly relevant when 
deciding whether to start therapy. Intraoperative US at the time of surgery can help differentiate 
tumor from just abnormal glomeruli. 
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There are a variety of techniques in the literature to help with operative resection. In many cases 
simple manual compression is adequate.56-58 Other adjuncts include vessel clamping, 
hypothermia, perfusion solution (not widely used and in small children may promote vascular 
thrombosis), and in rare cases ex vivo resection and autotransplantation. The kidney and tumor 
should be completely exposed to identify and isolate mesenteric and renal vessels. Tension on 
the vessels is associated with venous thrombosis. The tumor is excised by scoring the renal 
surface and carefully separating the tumor and a surrounding rim of normal parenchyma from the 
adjacent tissue. Intraoperative ultrasound can use to delineate the tumor in situ to help define 
resection margins both before and after the tumors has been removed. Enucleation is okay with 
favorable histology but the kidney will need to be irradiated to prevent recurrence. If the child 
has anaplastic histology, the margins need to be negative. For intracalyceal tumors, ureteroscopy 
is helpful to ensure that all involved urothelial tissue has been resected. Collecting system entry 
is managed with antegrade placement of a ureteral stent, closure of the collecting system with 
absorbable suture, and placement of external drains.  If possible, the kidney is folded together 
over thrombin-soaked gel foam, and approximated with interrupted horizontal mattress sutures.   
 
Long term outcomes, what influences them and how can surgery play a role as part of first 
line therapy in mitigating the use of therapies that carry these risks 
The long-term outcome of patients with WT is underscored by the burden of treatment received. 
Overall outcome over the different study groups are excellent but some specific subgroups of 
patients need to be more closely investigated and collaborative studies will be of major benefit 
owing to the small number of patients to include in each (anaplastic WT, BWT, and metastatic 
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WT).  The role for a surgeon is to perform a complete operation. Failure to sample lymph nodes 
is the most common mistake by surgeons. In addition avoiding an intraoperative spill is critical 
as this can influence treatment and subsequent long term effects.59  
Long-term renal function is of major concern, not only for BWT but also for unilateral WT. 
Among 9,237 patients enrolled by North American institutions on 1 of 5 NWTS protocol studies 
between 1969 and 2002, the cumulative incidence of end stage renal disease (ESRD) due to 
chronic renal failure 20 years after WT diagnosis for either type in non-syndromic patients was 
1.7%.60  For patients with non-syndromic unilateral FH histology WT, it was 0.6%. For ESRD 
due to progressive BWT, the incidence was 4.0% at 3 years after diagnosis in patients with 
synchronous BWT and 19.3% in those with metachronous BWT. The risk factors associated with 
ESRD due to chronic renal failure were stromal predominant histology (HR 6.4, 95% CI 3.4, 
11.9; p<0.001), intralobar NR (HR 5.9, 95% CI 2.0, 17.3; p=0.001), and diagnosis at less than 24 
or 48 months (HR 1.7 and 2.8 respectively, p=0.003) 61 For WT1 syndromic patients, 20-year 
ESRD cumulative incidence was 82.7% for Denys-Drash, 43.3% for WAGR and 9.4% in 
patients with genito-urinary anomalies .61 In addition, the wider availability and accuracy of 
genomic technologies may identify more WT genes and molecular fingerprints with unknown 
implications for renal function into adulthood. 
 
Conclusion Despite the good overall survival outcomes of most patients with WT, greater efforts 
are still needed to decrease the late effects of surgery combined with more accurate risk-stratified 
use of chemotherapy and radiotherapy. The emerging very long-term follow-up data, particularly 
in the light of newly discovered genetics, will increase our knowledge of WT treatment burden 
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and predisposing factors for renal function and toxicity. More accurate radiological assessment 
in the preoperative phase with the development of DWI-MRI allowing a better surgical planning 
of the resection (total nephrectomy versus NSS) and also determining the best timing for surgery 
in both unilateral and BWT should add great value in adapting and personalizing treatment 
modalities for each patient. This could be ultimately achieved through international collaboration 
and increased centralized data collection. In this setting, surgeons must be more aware and 
cognizant of preoperative and postoperative treatment possibilities to achieve the most optimal 
results for the treatment of patients with WT. 
Future studies may examine: 
1. The biological basis of 1-q gain and its role as an adverse prognostic biomarker to stratify 
patients  
2. Can the surgery only approach be expanded to a wider group of patients based on recent 
biological insights?  
3. What is the role of molecularly targeted agents in the treatment of very high risk and 
relapsed WT patients ? 
4. Specific surgical questions may include 
a. What are the minimum number of lymph nodes need to properly asses the risk of 
disease 
b. Is there a role for thorascopic surgery to avoid pulmonary radiation in children 
with stage IV WT who  partially respond to three drug chemotherapy 
c. The long term outcomes  and impact on renal function of  partial nephrectomy  in 
unilateral WT needs further study, and in relation to the underlying genetics    
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Figure and Table Legends 
 
Table 1- Staging systems for SIOP and COG 
 Table 2 -4 year event free and overall survival of COG studies ARENO 532, 533 and 321.  
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SIOP and COG Staging Systems 
SIOP Staging  
 
Stage Criteria 
I The tumor is limited to the kidney or surrounded with a fibrous pseudocapsule if 
outside the normal contours of the kidney and is completely resected. The tumor 
may be protruding (bulging) into the pelvic system and dipping into the ureter, but 
it is not infiltrating their walls. The vessels of the renal sinus are not involved. 
Intrarenal vessels may be involved. Presence of necrotic tumor in the renal sinus or 
peri-renal fat does not upstage to stage II. Percutaneous cutting needle biopsy is 
allowed. 
II The tumor extends beyond the kidney or penetrates through the renal capsule 
and/or fibrous pseudocapsule into the perirenal fat, but is completely resected. The 
tumor infiltrates the renal sinus and/or invades blood and lymphatic vessels 
outside the renal parenchyma, but it is completely resected en bloc. The tumor 
infiltrates adjacent organs or vena cava, but is completely resected. Percutaneous 
cutting needle biopsy is allowed. 
III Incomplete excision of the tumor, which extends beyond resection margins (gross 
or microscopic tumor remains postoperatively). Any abdominal lymph nodes are 
involved. Tumor rupture before or during surgery (irrespective of other criteria for 
staging). The tumor has penetrated the peritoneal surface. Tumor implants are 
found on the peritoneal surface. The tumor thrombi present at resection, margins of 
vessels or ureter transected or removed piecemeal by surgeon. The tumor has been 
surgically biopsied (wedge or open biopsy) prior to preoperative chemotherapy or 
surgery. 
IV Hematogenous metastases (lung, liver, bone, brain, etc.) or lymph node metastases 
outside the abdominopelvic region. 
V Bilateral renal tumors at diagnosis. Each side has to be substaged according to the 
above classifications. 
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COG Staging 
Stage Criteria 
I The tumor is limited to the kidney and has been completely resected 
The tumor was not ruptured or biopsied prior to removal. 
No penetration of the renal capsule or involvement of renal sinus vessels.  
 
 
II The tumor extends beyond the capsule of the kidney but was completely resected 
with no evidence of tumor at or beyond the margins of resection. 
There is penetration of the renal capsule OR 
There is invasion of the renal sinus vessels 
 
III Gross or microscopic residual tumor remains postoperatively including: 
 inoperable tumor, positive surgical margins, tumor spillage surfaces, regional 
lymph-node metastases, positive peritoneal cytology or transected tumor 
thrombus  
The tumor was ruptured or biopsied prior to removal. 
 
IV Haematogenous metastases or lymph-node metastases outside the abdomen (eg, 
lung, liver, bone, brain).  
 
 
V Bilateral renal involvement is present at diagnosis and each side may be 
considered to have a stage.  
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 Table 2 Outcomes of COG studies 532, 533 and 321 
Study # 
Patients 
Chemotherapy  
Regimen 
4 year EFS/OS 
Very Low Risk Surgery Only 
FH ( Study ARENO532) 
116 none  EFS 89.7 
OS 100% 
Stage I and II 
Combined1p and 16 q LOH 
positive  FH (Study 
ARENO533) 
35 DD4A EFS 83.9%  
OS 100% 
Stage III  
Combined 1p and 16  LOH 
positive (Study ARENO533) 
52 M plus XRT  EFS 91.5% 
 OS 97.8%  
Stage IV lung nodules 
incomplete responders 
(Study ARENO533) 
183 M plus XRT   EFS 88% OS 
92% 
Stage IV  lung nodules 
complete responders at 6 
weeks (Study ARENO533) 
119 DD4A EFS 80% 
OS 98.3% 
High Risk Wilms Tumor 
  AH  
Stage II 
Stage III 
Stage IV 
(Study ARENO321) 
 
 
23 
24 
46 
 
 
Revised UH-1 
+/- XRT 
. 
 
OS 85% 
OS 74% 
OS 46% 
Legend 
FH= Favourable Histology Wilms Tumor                                                                                          
AH= Anaplastic Histology Wilms tumor                                                                                       
DD-4A = Vincristine, dactinomycin doxorubicin                                                                                         
Regimen M= Vincristine, dactinomycin doxorubicin cyclophosphamide and etoposide .    
Revised UH-1= Vincristine, dactinomycin doxorubicin cyclophosphamide carboplatin,etoposide 
and radiation 
XRT= radiation  
 
 
 
 
 
